KRAS and neoplasm: With treatments targeting these mutations becoming increasingly available, reliable detection of mutations is essential.<h4>Methods</h4>The frequency of <i>KRAS</i> and <i>GNAS</i> mutations was analyzed in tumor samples from 167 patients with verified PMP using targeted DNA sequencing and/or droplet digital polymerase chain reaction.